^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD28 agonist

    Related drugs:
    4d
    MDX-2001-101: Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=285, Recruiting, ModeX Therapeutics, An OPKO Health Company | N=115 --> 285
    Enrollment change • First-in-human
    5d
    A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=228, Recruiting, Regeneron Pharmaceuticals | N=370 --> 228 | Trial completion date: Jan 2027 --> Mar 2030 | Trial primary completion date: Jan 2027 --> Mar 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    nezastomig (REGN5678)
    6d
    ATHENA-1: A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=107, Recruiting, Regeneron Pharmaceuticals | Trial completion date: May 2029 --> Jan 2030 | Trial primary completion date: Jun 2027 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    Ordspono (odronextamab) • REGN5837
    6d
    A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=355, Recruiting, Janssen Research & Development, LLC | N=250 --> 355
    Enrollment change
    |
    apalutamide • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • JNJ-6143 • pasritamig (JNJ-8343)
    11d
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC (clinicaltrials.gov)
    P1, N=138, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    12d
    Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=400, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • MUC17 (Mucin 17)
    |
    MSI-H/dMMR
    |
    alveltamig (ZG006)
    14d
    R17372-HM-2493: A Trial to Study if REGN17372 in Combination with Linvoseltamab is Tolerable for Adult Participants with Relapsed/Refractory Multiple Myeloma (2025-522776-93-00)
    P1, N=26, Not yet recruiting, Regeneron Pharmaceuticals Inc.
    New P1 trial • First-in-human
    |
    Lynozyfic (linvoseltamab-gcpt)
    25d
    A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    Lynozyfic (linvoseltamab-gcpt)
    1m
    A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=300, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    ubamatamab (REGN4018) • Kevzara (sarilumab)
    2ms
    RNDO-564-001: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 (clinicaltrials.gov)
    P1, N=149, Enrolling by invitation, Rondo Therapeutics | Recruiting --> Enrolling by invitation
    Enrollment status
    |
    Keytruda (pembrolizumab)
    2ms
    A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Regeneron Pharmaceuticals
    New P1/2 trial • First-in-human
    |
    Lynozyfic (linvoseltamab-gcpt)
    2ms
    Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Recruiting, ModeX Therapeutics, An OPKO Health Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive